{ "id": "covid-severe-illness", "slug": "covid", "topic": "Vaccines", "tag": "COVID vaccines", "revision": "vaccine-2026-10-15", "locale": "en", "assessment": "Source-grounded explanation · research draft", "title": "COVID vaccines are safe and effective", "signLines": [ "COVID vaccines", "are safe", "and effective" ], "question": "How do COVID vaccines protect against serious illness?", "summary": "COVID vaccines reduce severe illness, hospital treatment and deaths. Updated doses can add protection after earlier vaccination or infection. Protection against infection fades. Serious side effects are rare; benefits and risks depend on age, health and vaccine.", "scope": "", "geographicScope": { "kind": "global", "countryCodes": [], "jurisdictionCodes": [], "note": "Evidence and jurisdiction limits are stated beside the relevant claims." }, "evidence": [ { "id": "covid-protection", "heading": "Updated vaccines can add protection", "text": "In a US study of adults without immune suppression, a 2025–26 dose was associated with 55% lower risk of COVID hospitalization than no current-season dose (95% confidence interval 41–66%). Encounters were from September–December 2025, with a median 46 days since vaccination. This is relative effectiveness from an observational comparison—not a 55-percentage-point reduction or a year-long estimate for everyone.", "sources": [ 1 ], "detailTopics": [], "sourceIds": [ "vaccine-update-c1" ] }, { "id": "covid-study", "heading": "Infection and serious illness are different outcomes", "text": "Protection against infection is incomplete and fades. Earlier infection also contributes immunity. The useful question is how much an updated dose adds against a particular outcome. A separate study of mostly older male US veterans found protection against hospitalization and death; it cannot supply a young healthy person’s absolute benefit.", "sources": [ 1, 2 ], "detailTopics": [], "sourceIds": [ "vaccine-update-c1", "vaccine-update-c2" ] }, { "id": "covid-safety", "heading": "Safety and side effects", "text": "Most reactions pass quickly. Myocarditis is a real, rare risk after mRNA vaccines, with higher risk in adolescent and young adult males and differences by product and dose. Infection does not always carry more myocarditis risk than every vaccine dose in every subgroup.", "sources": [ 3, 4 ], "detailTopics": [ "covid-vaccine-harms" ], "quickLink": "Safety and side effects", "sourceIds": [ "vaccine-update-c3", "vaccine-update-c4" ] }, { "id": "covid-mortality", "heading": "Large studies test claims of widespread harm", "text": "A French study of adults aged 18–59 found no increased overall mortality over nearly four years. Differences between vaccinated and unvaccinated people can affect the comparison. The deaths page explains both this population evidence and rare fatal reactions; cancer and pregnancy have their own evidence pages.", "sources": [ 5 ], "detailTopics": [ "covid-vaccine-deaths", "covid-cancer-dna", "covid-pregnancy" ], "sourceIds": [ "vaccine-update-d1" ] } ], "takeaway": "COVID vaccines reduce severe illness, hospital treatment and deaths.", "limits": [ "The findings apply to the vaccines, populations and outcomes studied. Personal recommendations depend on your health and current local guidance." ], "contextTitle": "", "contextIntro": "", "detail": "", "sources": [ { "id": "vaccine-update-c1", "title": "Interim Estimated Effectiveness of 2025–2026 COVID-19 Vaccines in Adults Using a Test-Negative Design", "publisher": "JAMA Network Open, 2026", "url": "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2850668", "readerBlurb": "US immunocompetent adults, September–December 2025; compares a current-season dose with none, with short follow-up.", "limit": "US immunocompetent adults, September–December 2025; compares a current-season dose with none, with short follow-up.", "access": "Mapped to the 14 October 2026 research archive; selected fresh checks and access limits recorded in output/live-review/vaccine-content/independent-source-review.md.", "revision": "research-2026-10-15", "retrievedAt": "2026-10-14", "locale": "en", "type": "Evidence source", "geographicCoverage": { "kind": "undetermined", "countryCodes": [], "jurisdictionCodes": [], "note": "US immunocompetent adults, September–December 2025; compares a current-season dose with none, with short follow-up." }, "publicationTitle": "Interim Estimated Effectiveness of 2025–2026 COVID-19 Vaccines in Adults Using a Test-Negative Design", "archiveDate": "2026-10-14", "supports": [ "Updated vaccines can add protection", "Infection and serious illness are different outcomes" ], "limitationsInternal": [ "Mapped to the 14 October 2026 research archive; selected fresh checks and access limits recorded in output/live-review/vaccine-content/independent-source-review.md.", "US immunocompetent adults, September–December 2025; compares a current-season dose with none, with short follow-up." ], "limitationsPublic": [ "US immunocompetent adults, September–December 2025; compares a current-season dose with none, with short follow-up." ] }, { "id": "vaccine-update-c2", "title": "Association of 2024–2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans", "publisher": "New England Journal of Medicine, 2025", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2510226", "readerBlurb": "Observational US veteran study with a flu-vaccinated comparator; mostly older men, not every age group.", "limit": "Observational US veteran study with a flu-vaccinated comparator; mostly older men, not every age group.", "access": "Mapped to the 14 October 2026 research archive; selected fresh checks and access limits recorded in output/live-review/vaccine-content/independent-source-review.md.", "revision": "research-2026-10-15", "retrievedAt": "2026-10-14", "locale": "en", "type": "Evidence source", "geographicCoverage": { "kind": "undetermined", "countryCodes": [], "jurisdictionCodes": [], "note": "Observational US veteran study with a flu-vaccinated comparator; mostly older men, not every age group." }, "publicationTitle": "Association of 2024–2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans", "archiveDate": "2026-10-14", "supports": [ "Infection and serious illness are different outcomes" ], "limitationsInternal": [ "Mapped to the 14 October 2026 research archive; selected fresh checks and access limits recorded in output/live-review/vaccine-content/independent-source-review.md.", "Observational US veteran study with a flu-vaccinated comparator; mostly older men, not every age group." ], "limitationsPublic": [ "Observational US veteran study with a flu-vaccinated comparator; mostly older men, not every age group." ] }, { "id": "vaccine-update-c3", "title": "FDA Approves Required Updated Warning in Labeling of mRNA COVID-19 Vaccines Regarding Myocarditis and Pericarditis", "publisher": "FDA, June 2025", "url": "https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-approves-required-updated-warning-labeling-mrna-covid-19-vaccines-regarding-myocarditis-and", "readerBlurb": "Observed 2023–24-formulation incidence in days 1–7 is not an excess-risk estimate. Persistent MRI findings have uncertain long-term meaning.", "limit": "Observed 2023–24-formulation incidence in days 1–7 is not an excess-risk estimate. Persistent MRI findings have uncertain long-term meaning.", "access": "Mapped to the 14 October 2026 research archive; selected fresh checks and access limits recorded in output/live-review/vaccine-content/independent-source-review.md.", "revision": "research-2026-10-15", "retrievedAt": "2026-10-14", "locale": "en", "type": "Evidence source", "geographicCoverage": { "kind": "undetermined", "countryCodes": [], "jurisdictionCodes": [], "note": "Observed 2023–24-formulation incidence in days 1–7 is not an excess-risk estimate. Persistent MRI findings have uncertain long-term meaning." }, "publicationTitle": "FDA Approves Required Updated Warning in Labeling of mRNA COVID-19 Vaccines Regarding Myocarditis and Pericarditis", "archiveDate": "2026-10-14", "supports": [ "Safety and side effects" ], "limitationsInternal": [ "Mapped to the 14 October 2026 research archive; selected fresh checks and access limits recorded in output/live-review/vaccine-content/independent-source-review.md.", "Observed 2023–24-formulation incidence in days 1–7 is not an excess-risk estimate. Persistent MRI findings have uncertain long-term meaning." ], "limitationsPublic": [ "Observed 2023–24-formulation incidence in days 1–7 is not an excess-risk estimate. Persistent MRI findings have uncertain long-term meaning." ] }, { "id": "vaccine-update-c4", "title": "Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex", "publisher": "Circulation, 2022", "url": "https://pubmed.ncbi.nlm.nih.gov/35993236/", "readerBlurb": "Historical English estimates use 28-day windows and vary by age, sex, product and dose; not current booster rates.", "limit": "Historical English estimates use 28-day windows and vary by age, sex, product and dose; not current booster rates.", "access": "Mapped to the 14 October 2026 research archive; selected fresh checks and access limits recorded in output/live-review/vaccine-content/independent-source-review.md.", "revision": "research-2026-10-15", "retrievedAt": "2026-10-14", "locale": "en", "type": "Evidence source", "geographicCoverage": { "kind": "undetermined", "countryCodes": [], "jurisdictionCodes": [], "note": "Historical English estimates use 28-day windows and vary by age, sex, product and dose; not current booster rates." }, "publicationTitle": "Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex", "archiveDate": "2026-10-14", "supports": [ "Safety and side effects" ], "limitationsInternal": [ "Mapped to the 14 October 2026 research archive; selected fresh checks and access limits recorded in output/live-review/vaccine-content/independent-source-review.md.", "Historical English estimates use 28-day windows and vary by age, sex, product and dose; not current booster rates." ], "limitationsPublic": [ "Historical English estimates use 28-day windows and vary by age, sex, product and dose; not current booster rates." ] }, { "id": "vaccine-update-d1", "title": "COVID-19 mRNA Vaccination and 4-Year All-Cause Mortality Among Adults Aged 18 to 59 Years in France", "publisher": "JAMA Network Open, 2025", "url": "https://doi.org/10.1001/jamanetworkopen.2025.46822", "readerBlurb": "Large observational comparison, median 45 months. Selection and health differences can affect all-cause mortality; does not settle pediatric risk.", "limit": "Large observational comparison, median 45 months. Selection and health differences can affect all-cause mortality; does not settle pediatric risk.", "access": "Mapped to the 14 October 2026 research archive; selected fresh checks and access limits recorded in output/live-review/vaccine-content/independent-source-review.md.", "revision": "research-2026-10-15", "retrievedAt": "2026-10-14", "locale": "en", "type": "Evidence source", "geographicCoverage": { "kind": "undetermined", "countryCodes": [], "jurisdictionCodes": [], "note": "Large observational comparison, median 45 months. Selection and health differences can affect all-cause mortality; does not settle pediatric risk." }, "publicationTitle": "COVID-19 mRNA Vaccination and 4-Year All-Cause Mortality Among Adults Aged 18 to 59 Years in France", "archiveDate": "2026-10-14", "supports": [ "Large studies test claims of widespread harm" ], "limitationsInternal": [ "Mapped to the 14 October 2026 research archive; selected fresh checks and access limits recorded in output/live-review/vaccine-content/independent-source-review.md.", "Large observational comparison, median 45 months. Selection and health differences can affect all-cause mortality; does not settle pediatric risk." ], "limitationsPublic": [ "Large observational comparison, median 45 months. Selection and health differences can affect all-cause mortality; does not settle pediatric risk." ] } ], "dossier": "vaccine-narratives-covid-2026-10-14.md", "supplementalDossiers": [ { "file": "vaccine_evidence_dossier.txt", "label": "Earlier supporting research" } ], "reviewNeeds": "Independent clinical/editorial approval remains pending; no personalized schedule.", "updateTriggers": "New studies, corrected sources, regulatory safety signals and changed local recommendations.", "related": [ { "slug": "covid-myocarditis", "label": "Heart inflammation", "reason": "See product, age and dose differences." }, { "slug": "covid-vaccine-deaths", "label": "Deaths and safety reports", "reason": "Understand population studies and reported deaths." }, { "slug": "covid-pregnancy", "label": "Pregnancy and fertility", "reason": "Read the separate mRNA evidence." } ], "presentation": "overview", "questions": [ { "slug": "covid-myocarditis", "label": "Heart inflammation", "description": "mRNA COVID vaccines can rarely cause heart inflammation" }, { "slug": "covid-vaccine-deaths", "label": "COVID vaccine deaths", "description": "COVID vaccines save lives" }, { "slug": "covid-vaccine-harms", "label": "COVID vaccine injuries", "description": "Serious COVID vaccine injuries are rare" }, { "slug": "covid-cancer-dna", "label": "COVID, cancer & DNA", "description": "COVID vaccines have not been shown to cause cancer" }, { "slug": "covid-pregnancy", "label": "COVID & pregnancy", "description": "mRNA COVID vaccines can protect during pregnancy" }, { "slug": "covid-vaccine-guidance", "label": "Personal vaccine advice", "description": "Who needs personal vaccine advice?" } ], "questionsHeading": "Find the answer you need", "shareContext": "Protection from serious COVID depends on age, health, previous infections or vaccines, and time since a dose.", "socialContext": "Protection varies with age, health, past infection or vaccines, and time since a dose.", "copyReviewedAt": "2026-10-15", "readerCopyEdition": "vaccine-clarity-2026-10-15", "citationDesignEdition": "publication-first-1", "assetDesignEdition": "space-first-1", "keyPoints": [ { "text": "A 2025–26 adult study estimated 55% protection against COVID hospitalization versus no current-season dose.", "sources": [ 1 ], "note": "US adults, September–December 2025; short follow-up." }, { "text": "Updated vaccination can add protection after earlier vaccination or infection.", "sources": [ 1, 2 ] }, { "text": "Protection against serious illness can remain even when infection occurs.", "sources": [ 1, 2 ] } ], "researchDate": "2026-10-14", "headline": { "text": "COVID vaccines are safe and effective", "revision": 1, "status": "draft", "sourceMessageId": null, "approvedAt": null, "authority": "Existing owner decisions recorded in AGENTS/D39; unavailable message IDs are not invented." }, "language": "en", "jurisdiction": { "kind": "global", "countryCodes": [], "jurisdictionCodes": [], "note": "Evidence and jurisdiction limits are stated beside the relevant claims." }, "claimScope": "", "research": { "dossierRef": "docs/research/vaccine-narratives-covid-2026-10-14.md", "reviewedAt": "2026-10-14", "reviewDue": "New studies, corrected sources, regulatory safety signals and changed local recommendations.", "contraryEvidenceConsidered": [], "status": "research draft; editorial/context review separate" }, "status": "researched draft preview", "realWorldClaimReviewed": false, "clinicalEditorialApproved": false }